ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) Receives Average Rating of “Hold” from Brokerages

Shares of ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) have earned a consensus broker rating score of 3.00 (Hold) from the one brokers that provide coverage for the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a hold rating.

Zacks has also assigned ContraVir Pharmaceuticals an industry rank of 53 out of 256 based on the ratings given to related companies.

Several brokerages have weighed in on CTRV. Maxim Group reiterated a “buy” rating and issued a $3.00 price objective on shares of Actinium Pharmaceuticals in a research note on Wednesday, March 20th. ValuEngine cut shares of Zumiez from a “hold” rating to a “sell” rating in a research note on Tuesday, July 2nd.



Shares of NASDAQ CTRV traded down $0.03 during mid-day trading on Friday, reaching $4.01. 614,025 shares of the company were exchanged, compared to its average volume of 1,478,061. The firm’s 50-day moving average is $4.56. ContraVir Pharmaceuticals has a twelve month low of $3.52 and a twelve month high of $91.00.

ContraVir Pharmaceuticals (NASDAQ:CTRV) last posted its earnings results on Wednesday, May 15th. The biopharmaceutical company reported ($7.69) earnings per share (EPS) for the quarter.

An institutional investor recently raised its position in ContraVir Pharmaceuticals stock. Barclays PLC grew its position in ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) by 229.2% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 179,480 shares of the biopharmaceutical company’s stock after buying an additional 124,958 shares during the quarter. Barclays PLC owned 1.08% of ContraVir Pharmaceuticals worth $50,000 as of its most recent SEC filing. 1.07% of the stock is currently owned by institutional investors and hedge funds.

ContraVir Pharmaceuticals Company Profile

ContraVir Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of antiviral drugs with a primary emphasis on the treatment of Hepatitis B virus (HBV) infections. It engages in the development of TXL, a lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of the active antiviral agent tenofovir diphosphate for the treatment of Hepatitis B; and CRV431, a novel drug candidate for the treatment of chronic HBV infection.

Featured Article: Stock Portfolio Tracker

Get a free copy of the Zacks research report on ContraVir Pharmaceuticals (CTRV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ContraVir Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraVir Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.